Related Experiment Video
Updated: Nov 3, 2025
04:40
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
2.8K
Sticky Issues: What APs Need to Know About Anticoagulants and Patients With Cancer
1University of Kentucky, Lexington, Kentucky.
Journal of the Advanced Practitioner in Oncology
|June 4, 2021
Summary
Direct oral anticoagulants (DOACs) offer new options for cancer patients facing venous thromboembolism. This expert discussion covers patient selection, drug comparisons, and current data for prevention and treatment.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Cancer patients have a high risk of venous thromboembolism (VTE).
- Direct oral anticoagulants (DOACs) are increasingly used for VTE management.
- Optimal use of DOACs in cancer patients requires careful consideration.
Purpose of the Study:
- To guide the selection of cancer patients suitable for DOAC therapy.
- To compare the characteristics of available DOACs.
- To review recent evidence on VTE prevention and treatment in cancer.
Main Methods:
- Expert presentation at JADPRO Live Virtual 2020.
- Review of clinical data and guidelines.
- Discussion of pharmacological profiles and clinical trial outcomes.
Main Results:
- Framework for identifying appropriate patients for DOACs.
- Analysis of DOAC efficacy, safety, and dosing.
- Summary of current evidence for VTE prophylaxis and treatment in malignancy.
Conclusions:
- DOACs represent a significant advancement in managing VTE in cancer.
- Personalized treatment selection based on patient and drug factors is crucial.
- Ongoing research continues to refine the role of DOACs in oncology practice.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
01:29Venous Thrombosis III: Interprofessional Care
86
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
86
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
01:30Venous Thrombosis IV: Nursing Management
65
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
65
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
797
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
797
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
85
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
85